Mobile

A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Pro...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011018-51

A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective: - To determine whether afamelanotide can reduce the severity of phototoxic reactions in patients with EPP.

Critère d'inclusion

  • Erythropoietic Protoporphyria (EPP)

Liens